Show simple item record

dc.contributor.authorKvistad, Christopher Elnan
dc.contributor.authorNovotny, Vojtech
dc.contributor.authorKurz, Martin
dc.contributor.authorRønning, Ole M.
dc.contributor.authorThommessen, Bente
dc.contributor.authorCarlsson, Maria
dc.contributor.authorWaje-Andreassen, Ulrike
dc.contributor.authorNæss, Halvor
dc.contributor.authorThomassen, Lars
dc.contributor.authorLogallo, Nicola
dc.date.accessioned2020-04-15T20:53:32Z
dc.date.available2020-04-15T20:53:32Z
dc.date.issued2019-04-08
dc.description.abstract<p><i>Background and Purpose — </i>Tenecteplase represents a promising alternative to alteplase as thrombolytic treatment in acute ischemic stroke. There are limited data on tenecteplase 0.4 mg/kg in patients with increased stroke severity. We aimed to assess safety and efficacy of tenecteplase 0.4 mg/kg in patients with moderate and severe ischemic stroke. <p><i>Methods — </i>NOR-TEST (Norwegian Tenecteplase Stroke Trial) was a phase III trial designed to investigate the safety and efficacy of tenecteplase 0.4 mg/kg versus alteplase 0.9 mg/kg in ischemic stroke. In this post hoc analysis, moderate stroke was defined as admission National Institutes of Health Stroke Scale; 6 to 14 and severe stroke as National Institutes of Health Stroke Scale; ≥15. Rates of favorable outcome at 90 days, symptomatic intracerebral hemorrhage (sICH), and mortality after 7 and 90 days were assessed. <p><i>Results — </i>In patients with moderate stroke (n=261), there were no differences in rates of favorable outcome, sICH, or mortality between tenecteplase and alteplase. In patients with severe stroke (n=87), there were no differences in outcome, frequency of sICH, or mortality at 7 days, but all-cause mortality at 90 days was increased in patients treated with tenecteplase (10 [26.3%] versus 4 [9.1%]; <i>P</i>=0.045). One patient died of sICH in the tenecteplase group, and 2 patients died of sICH in the alteplase group. <p><i>Conclusions — </i>Rates of favorable outcome and sICH were similar between treatment groups in patients with moderate and severe stroke. Mortality after 90 days was increased in patients with severe stroke receiving tenecteplase. Future studies assessing tenecteplase 0.4 mg/kg should monitor safety parameters closely in patients with severe stroke.en_US
dc.identifier.citationKvistad CE, Novotny V, Kurz M, Rønning OM, Thommessen B, Carlsson M, Waje-Andreassen U, Næss H, Thomassen L, Logallo N. Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke. Stroke. 2019;50(5):1279-1281en_US
dc.identifier.cristinIDFRIDAID 1708377
dc.identifier.doi10.1161/STROKEAHA.119.025041
dc.identifier.issn0039-2499
dc.identifier.issn1524-4628
dc.identifier.urihttps://hdl.handle.net/10037/18041
dc.language.isoengen_US
dc.publisherAmerican Heart Associationen_US
dc.relation.journalStroke
dc.relation.projectIDinfo:eu-repo/grantAgreement/RCN/BEHANDLING/229006/Norway/The Norwegian Tenecteplase Stroke Trial - NOR-TEST (The Norwegian Stroke Project Part A)//en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2019 American Heart Association, Inc.en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750en_US
dc.titleSafety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke. Results From NOR-TESTen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record